Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients

Study summary

This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studied1,25 (OH)2 D3 and Inspiratory isometric resistance training

Plus 3 other study approaches.

Who it may be forCancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 26, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 4

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Mayo Clinic

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Phase 4
Sponsor: Mayo Clinic
Interventions being studied: Drug: 1,25 (OH)2 D3; Other: Inspiratory isometric resistance training; Drug: Oral Placebo; Other: Sham Inspiratory Isometric Resistance Training; Device: Threshold Inspiratory Muscle Trainer (IMT)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Diagnosis of cancer
Renal and hepatic function (creatinine \</= 2 x the institutional upper limit of normal; bilirubin \</= 2 x the institutional upper limit of normal)
No contraindication to receive either of the planned interventions of inspiratory resistance training or 1,25(OH)2D3 in the opinion of the healthcare provider
No difficulties with swallowing oral medications in the opinion of the enrolling physician

Reasons someone may not be able to joinExclusion criteria

Patient is taking calcium or Vitamin D supplements and is unwilling to stop for 8 weeks
Severe chronic obstructive pulmonary disease (oxygen dependent or patient self-reports unable to walk one block without difficulty)
Calcium or phosphorus level above the institutional upper limit of normal

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Mayo Clinic in RochesterRochester, Minnesota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 26, 2023. Always confirm current availability with the study team.

View original record ↗